Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(sacubitril valsartan)
709 results
  • Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. [Journal Article]
    J Am Coll Cardiol 2019; 74(23):2858-2873Shah AM, Cikes M, … PARAGON-HF Investigators
  • CONCLUSIONS: Diastolic dysfunction, left atrial enlargement, and pulmonary hypertension were common in PARAGON-HF. LV hypertrophy, elevated left- and right-sided pressures, and right ventricular enlargement were independently predictive of incident heart failure hospitalization or cardiovascular death. Echocardiographic differences among HFpEF trials despite similar clinical event rates highlight the heterogeneity of this syndrome. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
  • [Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease]. [Journal Article]
    Dtsch Med Wochenschr 2019; 144(24):1714-1720Heine GH, Rogacev KS
  • Medical management of patients with co-existing Heart Failure with reduced Ejection Fraction (HFrEF) and chronic kidney disease (CKD) poses a significant challenge to treating physicians. On the one hand, the traditional therapeutic strategies such as betablockers, angiotensin converting enzyme inhibiotors, angiotensin receptor blockers and mineralocorticoid receptor antagonists have been evaluat…
  • Medical Therapies for Heart Failure With Preserved Ejection Fraction. [Journal Article]
    Hypertension 2019; :HYPERTENSIONAHA11914057Kjeldsen SE, von Lueder TG, … Zannad F
  • Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection fraction. Over the past 16 years, 4 prospective, randomized, placebo-controlled clinical trials using candesartan, perindopril, irbesartan, and…
New Search Next